STOCK TITAN
  1. Home
  2. Sec-filings
  3. INCY
  4. [8-K] INCYTE CORP Reports Material Event

Incyte (NASDAQ: INCY) secures CMS deal, books $246M non-cash benefit

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Incyte Corporation has reached a settlement with the Centers for Medicare & Medicaid Services regarding how Medicaid rebate rules apply to Opzelura (ruxolitinib) cream. CMS will not treat Opzelura as a line extension of Jakafi for rebate purposes, and Incyte has withdrawn its related lawsuit. The company expects to record a one-time, non-cash benefit of approximately $246 million in the quarter ending June 30, 2026, reflecting reversal of accruals previously recorded through March 31, 2026. Incyte will stop accruing for potential line extension liabilities on Opzelura and anticipates better gross-to-net performance for the product going forward. The company plans to update its financial guidance to reflect the settlement in its next earnings release.

Positive

  • One-time $246 million non-cash benefit expected in the quarter ending June 30, 2026 from reversing accruals related to potential Medicaid line extension liabilities on Opzelura.
  • Favorable CMS treatment of Opzelura, which will not be treated as a line extension of Jakafi for Medicaid rebate purposes, removes a legal and financial overhang.
  • Expected improvement in Opzelura’s gross-to-net on a go-forward basis as the company will no longer accrue for potential line extension regulation liabilities.

Negative

  • None.

Insights

CMS settlement removes a rebate overhang and adds a $246M non-cash boost.

The agreement between Incyte and CMS means Opzelura will not be treated as a line extension of Jakafi for Medicaid rebate calculations. This resolves ongoing litigation and reverses previously established accruals tied to potential line extension liabilities.

Incyte expects a one-time, non-cash benefit of about $246 million in the quarter ending June 30, 2026, driven by reversal of accruals through March 31, 2026. While non-cash, this materially lifts reported earnings for that period.

The company will no longer accrue for these potential liabilities and expects an improved gross-to-net profile for Opzelura. Future earnings releases, starting with the next scheduled report when guidance is updated, will clarify how much this changes projected profitability for the product and overall margins.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
One-time non-cash benefit $246 million Expected in Q2 ending June 30, 2026 from reversal of accruals
Accrual period reversed Through March 31, 2026 Accrual balances for potential Medicaid line extension liabilities
Products in CMS agreement Opzelura and Jakafi Opzelura not treated as line extension of Jakafi for Medicaid rebates
Quarter of expected benefit Quarter ending June 30, 2026 Timing of recording the $246 million non-cash benefit
Medicaid rebate rules regulatory
"litigation related to the application of Medicaid rebate rules to Opzelura"
line extension regulation regulatory
"CMS will not apply the line extension regulation to Opzelura"
gross-to-net financial
"expects an improvement to Opzelura’s gross-to-net on a go-forward basis"
Gross-to-net describes the difference between a product’s total billed sales (the “sticker” or list price) and the cash a company actually keeps after subtracting discounts, rebates, returns and other deductions. For investors it matters because large or growing deductions can make reported sales look strong on paper while actual revenue and profit are much smaller, similar to a store advertising high prices but taking many coupons at checkout.
non-cash benefit financial
"expects to record a one-time, non-cash benefit of approximately $246 million"
financial guidance financial
"plans to update financial guidance to reflect the impact of the settlement"
Financial guidance is the information that a company provides about its expected future financial performance, such as sales, profits, or expenses. It helps investors understand what the company aims to achieve and plan their decisions accordingly, much like a forecast or a roadmap that indicates the company's future direction. This guidance influences investor confidence and decision-making, as it offers insight into the company's outlook and growth expectations.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
FALSE000087916900008791692026-04-282026-04-28

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 22, 2026
INCYTE CORPORATION
(Exact name of registrant as specified in its charter)
Delaware001-1240094-3136539
(State or Other Jurisdiction of
Incorporation)		(Commission File Number)(I.R.S. Employer
Identification No.)
1801 Augustine Cut-Off
Wilmington, DE
19803
(Address of principal executive offices)(Zip Code)
(302) 498-6700
(Registrant’s telephone number,
including area code)
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of exchange on which registered
Common Stock, $.001 par value per shareINCYThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b—2 of the Securities Exchange Act of 1934 (§ 240.12b—2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o


Item 8.01 Other Events.
Incyte Corporation (the “Company”) today announced that it has reached an agreement with the Centers for Medicare & Medicaid Services (“CMS”) to resolve the Company’s litigation related to the application of Medicaid rebate rules to Opzelura® (ruxolitinib) cream. Under the agreement, CMS will not apply the line extension regulation to Opzelura as if it were a line extension of Jakafi® (ruxolitinib), and the Company has withdrawn its lawsuit challenging the regulations. The settlement was reached based on the unique facts of Opzelura and Jakafi.

The Company expects to record a one-time, non-cash benefit of approximately $246 million in the second quarter ending June 30, 2026, associated with the reversal of previously established accrual balances through March 31, 2026, related to liabilities associated with the potential application of the line extension regulations to Opzelura. The Company will no longer accrue for the potential application of the line extension regulations to Opzelura and expects an improvement to Opzelura’s gross-to-net on a go-forward basis. The Company plans to update financial guidance to reflect the impact of the settlement during the next scheduled earnings release.

2

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 22, 2026
INCYTE CORPORATION
By:/s/ Suketu Upadhyay
Suketu Upadhyay
Executive Vice President and Chief Financial Officer
3

Source: View Original Filing on SEC EDGAR

FAQ

What did Incyte (INCY) announce about its CMS Medicaid rebate dispute?

Incyte announced a settlement with CMS over how Medicaid rebate rules apply to Opzelura cream. CMS will not treat Opzelura as a line extension of Jakafi, and Incyte has withdrawn its lawsuit challenging the line extension regulations for this product.

How much is the one-time financial benefit Incyte expects from the CMS settlement?

Incyte expects a one-time, non-cash benefit of about $246 million in the second quarter ending June 30, 2026. This comes from reversing accruals previously recorded through March 31, 2026 for potential line extension-related Medicaid rebate liabilities on Opzelura.

How will the CMS settlement affect Incyte’s future accounting for Opzelura (INCY)?

Incyte will stop accruing liabilities for the potential application of Medicaid line extension regulations to Opzelura. The company also expects Opzelura’s gross-to-net performance to improve going forward, which could enhance reported net sales from this product versus prior assumptions.

What happens to Incyte’s lawsuit against CMS after the Opzelura settlement?

Incyte has withdrawn its lawsuit challenging the Medicaid line extension regulations as they relate to Opzelura and Jakafi. The settlement, based on the unique facts of these products, effectively ends that specific litigation and clarifies how CMS will treat Opzelura rebates.

Will Incyte (INCY) change its financial guidance because of the CMS agreement?

Incyte plans to update its financial guidance to reflect the settlement’s impact. The company stated it will provide revised guidance during its next scheduled earnings release, incorporating the one-time non-cash benefit and changes in Opzelura’s gross-to-net expectations.

Which products are involved in Incyte’s CMS Medicaid rebate settlement?

The settlement concerns Opzelura (ruxolitinib) cream and Jakafi (ruxolitinib). CMS agreed not to apply the Medicaid line extension regulation to Opzelura as if it were a line extension of Jakafi, influencing rebate treatment and related accruals.

Filing Exhibits & Attachments

3 documents

Other Documents